Pharmacy Medical News about Neoplasms Pain Administration, Cutaneous Fentanyl

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The Use of Transdermal Fentanyl in Cancer Pain: A Compliance Study of Outpatients in Taiwan
American Journal of Hospice and Palliative Medicine, 10/05/09

Chiou T–J et al. – From 2005 to 2006, 822 outpatients received TTS–F to collect pain assessment forms and diaries for 4 weeks. Most (78.7%) patients were initially prescribed 25 microg/h TTS–F. Doses were adjusted weekly at clinicians' discretion, according to pain assessment and side effects. Patients receiving 50 microgg/h, 75 microgg/h, and > 75 microgg/h TTS–F had increased from 17.5% to 32.1%, 1.8% to 3.4%, and 1.9% to 2.2%, respectively, by week 2; further small increases were found in weeks 3 and 4. Pain palliation improved from 60.6% during week 1 to 78.6% at week 4. The common adverse effects were nausea/vomiting. Patient’s compliance was >90%. This study found that the TTS–F is effective and well tolerated.

Exclusive Author Commentary
Tzeon-Jye Chiou, 10/05/09

This is the first article to describe the use of TTS-F in the treatment of pain in advanced cancer patients in Taiwan. It is a valuable article to describe the use of TTS-F as a fist step or second step to treat cancer pain in advanced cancer patients. The result just shows us that the early use of TTS-F in cancer pain is worthful for cancer pain and results in lower incidence of opioid related toxicity.

<< Previous
Relationship of CYP2D6 genetic polymorphisms and the...

Next >>
Antibiotic-resistant pathogens in intensive care units